Arranon
(nelarabine)ApprovedSmall molecule
NovartisNelarabine is a chemotherapy medication used to treat certain types of blood cancers, specifically leukemia and lymphoma that have not responded to other treatments or have returned after previous therapy. It works by destroying cancer cells.[2] Arranon is currently approved and in use across 11 indications[4].[1]
Arranon is one of 144 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.
11
Indications
31
Total Trials
8
Active Trials
143
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Arranon
NovartisApproved
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Oncaspar
SServier
Phase 3
Fludara
SanofiPhase 3
Medrol
PfizerPhase 3
Iclusig
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia7 trials
Show 4 more trials
T-cell acute lymphoblastic leukemia5 trials
Leukemia3 trials
Lymphoma2 trials
12 more indications
Relapse1 trial
Lymphoid Malignancies1 trial
Lymphoblastic Lymphoma1 trial
Cutaneous T-cell lymphoma1 trial
Chronic Lymphocytic Leukemia1 trial
Treatment1 trial
T lymphoblastic leukemia/lymphoma1 trial
Regulatory
FDA Approval Timeline[5]
Oct 28, 2005
ARRANON
NDA NDA021877
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Arranon drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for nelarabine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]